Chronic Airway Disease, Mucus Rheology and Exacerbations
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Azithropycin according to symptoms
- Registration Number
- NCT04339270
- Lead Sponsor
- University Hospital, Montpellier
- Brief Summary
The main objective of this trial is to compare the exacerbation number over 12 months of follow-up between a group of patients with COPD treated according to standardized management (azithromycin prescribed in the event of severe sputum according to the CASA-Q score , standardized comparator arm) and a similar group in which azithromycin is prescribed based on mucus rheology (experimental arm) or CASA-Q.
- Detailed Description
The secondary objectives are to compare between the 2 arms:
* exacerbation number according to their severity (observed throughout the duration of the study);
* the evolution of the symptoms, the rheology of the sputum, and the pulmonary function (measurements repeated every three months);
* medication consumption and adverse events (monitored throughout the duration of the study);
* patient trajectories during follow-up;
* the overall clinical improvement at the end of the study and the evolution of the quality of life (measurements repeated every 3 months);
* the change in biomarkers of interest (baseline versus end of study).
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 72
- Subjets between 40 - 85 years (included)
- Written and signed informed consent form
- Subjects must be able to attend all planned visits and comply with all test procedures
- Beneficiary of or affiliated with the French social security system
- Man or woman with chronic obstructive pulmonary disease for at least 1 year defined according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria and validated by the clinical investigator
- Optimal treatment according to GOLD class severity C or D recommendations
- >=3 exacerbation (regardless of severity: mild-moderate-severe) or ≥ 1 severe exacerbations (requiring hospitalization) in the past 12 months
- Spontaneous or induced sputum production
- Electrocardiogram: corrected distance between Q and T waves (QTC) <450 ms in men, QTC <470 ms in women
- Normal audiogram for age or absence of contraindication to azithromycin for long course according to Oto-Rhino-Laryngological specialist opinion
- Pregnancy or breastfeeding
- Patients who are prisoners or under other forms of judicial protection
- Patients under any form of guardianship
- Participation in another interventional protocol, (current or during the month preceding inclusion)
- Received azithromycin in the past 3 months
- Patient whose primary diagnosis is bronchial dilation based on CT scan documentation
- Known hypersensitivity to azithromycin, erythromycin, any other macrolide, ketolide or any of the excipients of the azithromycin-based specialty used
- Concomitant use of medication contraindicated with azithromycin (dihydroergotamine, ergotamine, cisapride, colchicine)
- Other respiratory diseases or associated lung infections
- Severe hepatic insufficiency and severe cholestasis (a liver biological test will be carried out if clinical suspicion)
- Renal impairment with creatinine clearance < 40 mL/min
- Patients with hematological malignancies who have undergone allogeneic hematopoietic stem cell transplantation
- Patients with galactose intolerance, Lapp lactase deficiency or glucose or galactose malabsorption syndrome (rare hereditary disease) due to the presence of lactose in the specialty Zithromax.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Azithromycin according to symptoms Azithropycin according to symptoms Patients randomized to this arm will be prescribed azithromycin in function of their symptoms. Azithromycin according to rheology Azithromycin according to rheology or symptoms Patients randomized to this arm will be prescribed azithromycin in function of their sputum rheology.
- Primary Outcome Measures
Name Time Method The main outcome measure is the number of exacerbations over the 12 months of follow-up. 12 months An exacerbation is defined according to French recommendations as an "acute event characterized by worsening of respiratory symptoms (notably cough, sputum and dyspnea) beyond \[normal\] daily variation and leading to a modification of treatment: either a simple increase in bronchodilators (in this case, a duration greater than 24 hours is required to define an exacerbation) or the addition of another treatment (antibiotic therapy and / or oral corticosteroid therapy)."
- Secondary Outcome Measures
Name Time Method COPD Assessment Test (CAT) 12 months Scores range from 0-40 with higher scores indicative of greater COPD impact on health status.
Sino Nasal Outcome Test 22 12 months The 22-question SNOT-22 is scored as 0 (no problem) to 5 (problem as bad as it can be) with a total range from 0 to 110 (higher scores indicate poorer outcomes).
Rheology: the viscous module (G '') 12 months Rheology: The ratio G '' / G ' 12 months Rheology: the critical constraint (tau-C). 12 months Spirometry: forced expiratory volume in 1 minute (FEV1) 12 months The number of mild exacerbations throughout follow-up 12 months A mild exacerbation does not require new additional medicine.
The number of moderate exacerbations throughout follow-up 12 months Moderate exacerbations require antibiotics or oral corticosteroids (but not hospitalization).
The number of severe exacerbations throughout follow-up 12 months Severe exacerbations require hospitalization.
Visual analogue scale for sputum production 12 months A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of sputum production possible).
Cough and sputum assessment questionnaire (CASA-Q) 12 months The four domains of the CASA-Q (cough/sputum symptom and impact) use scales from 0 to 100, with lower scores indicating higher symptom/impact levels. The 20-item questionnaire with a 7-day recall assesses the frequency and severity of cough and sputum and their impact on everyday life in clinical (trial) settings.
Visual analogue scale for coughing 12 months A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of coughing possible).
Rheology: modulus of elasticity of mucus (G ') 12 months Visual analogue scale for dyspnea 12 months A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of dyspnea possible).
Spirometry: forced vital capacity (FVC) 12 months Spirometry: FEV1/FVC 12 months Plethysmography for lung volumes: residual volume (RV) 12 months Plethysmography for lung volumes: functional residual capacity (FRC) 12 months Plethysmography for lung volumes: total lung capacity (TLC) 12 months Plethysmography for lung volumes: RV/TLC 12 months Drug consumption throughout the study. 12 months The number of adverse events will be recorded throughout the study. 12 months Episodes of exacerbation throughout the study 12 months For each exacerbation, the beginning and end dates will be recorded.
Episodes of hospitalization throughout the study 12 months For each hospitalization, the beginning and end dates will be recorded.
Clinical improvement 12 months Clinical improvement is scored via a point system from 0 to 3 at the end of the study. The points are added-up as follows:
* 1 point: no more than one exacerbation without hospitalization during the 52 weeks of follow-up;
* 1 point: gain \> 100mL in pre-bronchodilator FEV1 at the 52nd week compared to the baseline state;
* 1 point: variation of the CAT score during the 52 weeks of observation \> 2.Medical outcomes study 36-Item Short Form Survey (SF-36) 12 months The SF-36 taps eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. It also includes a single item that provides an indication of perceived change in health. A score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.
EQ-5D-5L 12 months In its original version, this self-administered questionnaire consists of two pages: the first contains the EQ-5D descriptive system and the second a visual analogue scale. The descriptive system has five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each described by five levels of intensity ("no problems", "slight problems", "moderate problems", "severe problems" and "extreme problems or complete inability"). The respondent must indicate one intensity level for each dimension.
St-George's Respiratory Questionnaire 12 months Scores range from 0 to 100, with higher scores indicating more limitations.
Blood cell differential: neutrophil levels 12 months A complete blood cell differential will be taken, including neutrophilia and eosinophilia.
Blood cell differential: eosinophil levels 12 months A complete blood cell differential will be taken, including neutrophilia and eosinophilia.
Serum Club cell secretory protein 12 months Sputum bacteriology 12 months
Trial Locations
- Locations (3)
University Hospitals of Bordeaux
🇫🇷Bordeaux, France
University Hospitals of Toulouse
🇫🇷Toulouse, France
University Hospitals of Montpellier
🇫🇷Montpellier, France